Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated: v3.5.2 added and v3.5.0 removed.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedSite revision indicator updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check48 days agoChange DetectedUpdated the page revision from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision: v3.4.2 was added. The funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check83 days agoChange DetectedA government funding lapse notice is now displayed on the page, and the site revision tag has been updated to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check90 days agoChange DetectedGlossary visibility was added and QC-related labels were updated to show the new revision (v3.4.0), replacing the previous version and capitalization variants.SummaryDifference0.2%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.